Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693387 | 0.89 | MAOA (0.44) | MAOAMAOBTSHRKMT2AMEN1 | |
| SCHEMBL2139565 | 0.89 | MAOA (0.39) | MAOAMAOBTSHRKMT2AMEN1 | |
| SCHEMBL12581334 | 0.88 | MAOA (0.41) | MAOAMAOBPTPRCKMT2AMEN1 | |
| SCHEMBL3911950 | 0.87 | MAOA (0.46) | MAOAMAOBTSHRKMT2AMEN1 | |
| SCHEMBL9201782 | 0.86 | TSHR (0.38) | MAOAMAOBTSHRKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL13269542 | 0.86 | MAOA (0.40) | MAOAMAOBPTPRCKMT2AMEN1 | |
| SCHEMBL22996130 | 0.86 | MAOA (0.49) | MAOAMAOBTSHRKMT2AMEN1 | |
| SCHEMBL397677 | 0.86 | CA2 (0.37) | MAOAMAOBTSHRPTPRCKMT2A | |
| SCHEMBL6535041 | 0.86 | MAOA (0.44) | MAOAMAOBPTPRCKMT2AMEN1 | |
| SCHEMBL3809747 | 0.85 | MAOA (0.39) | MAOAMAOBPTPRCKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113651721-A | Preparation method of 3- (tert-butyloxycarbonyl methylamino) propionic acid | 苏州昊帆生物股份有限公司 | 2021-11-16 | — | — | CN | claimed |
| EP-3891158-B1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-12247045-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| CN-113651721-A | Preparation method of 3- (tert-butyloxycarbonyl methylamino) propionic acid | 苏州昊帆生物股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113651721-A | Preparation method of 3- (tert-butyloxycarbonyl methylamino) propionic acid | 苏州昊帆生物股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113651721-A | Preparation method of 3- (tert-butyloxycarbonyl methylamino) propionic acid | 苏州昊帆生物股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-3789378-A1 | PIPERIDINES OR PIPERIDONES SUBSTITUTED WITH UREA AND HETEROARYL | Grünenthal GmbH (DE) | 2021-03-10 | — | — | EP | disclosed |
| EP-2831075-B1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1230220-A1 | BETA-AMINOACID COMPOUNDS USEFUL FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELI LILLY AND COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034571-A1 | β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0535192-B1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | HOFFMANN LA ROCHE (CH) | 1996-06-19 | — | — | EP | disclosed |
| US-5486466-A | ENZYME INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995020581-A1 | NOVEL HUMAN LEUKOCYTE ELASTASE (HLE) INHIBITORS, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SRI INTERNATIONAL (US) | 1995-08-03 | — | — | WO | disclosed |
| US-5399741-A | DNA gyrase inhibitors, process for their manufacture and pharmaceutical preparations containing same | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| US-5294609-A | Microbiocides | HOFFMANN-LAROCHE INC. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0535192-A1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME. | HOFFMANN LA ROCHE (CH) | 1993-04-07 | — | — | EP | disclosed |
| WO-1992018490-A1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055250-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K5, MAP4K1 | MAOA 1935/4885MAOB 1616/4885TSHR 4273/4885 |
| US-12247045-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K5, MAP4K1 | MAOA 1935/4885MAOB 1616/4885TSHR 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.